Volatility may be your only friend when it comes to investing in Atara Biotherapeutics

ATRA Stock  USD 2.86  0.11  3.70%   
In general, we focus on analyzing Atara (USA Stocks:ATRA) price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Atara Biotherapeutics daily price indicators and compare them against related drivers. Today's article will go over Atara Biotherapeutics. I will address few reasons this entity was abused by investors due to the current market volatility.
Published over a month ago
View all stories for Atara Biotherapeutics | View All Stories
Macroaxis uses a strict editorial review process to publish our stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Michael Smolkin

We provide trade advice to complement the prevailing expert consensus on Atara Biotherapeutics. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
About 99.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.97. Some equities with similar Price to Book (P/B) outperform the market in the long run. Atara Biotherapeutics recorded a loss per share of 3.65. The entity had not issued any dividends in recent years.
The successful prediction of Atara Biotherapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Atara Biotherapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Atara Biotherapeutics based on Atara Biotherapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Atara Biotherapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Atara Biotherapeutics's related companies.

Use Technical Analysis to project Atara expected Price

Atara Biotherapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Atara Biotherapeutics technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Atara Biotherapeutics trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for Atara Biotherapeutics, but it might be worth checking our own buy vs. sell analysis

Exercise or conversion by Gad Soffer of 4145 shares of Atara Biotherapeutics subject to Rule 16b-3

Legal trades by Atara Biotherapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Atara insider trading alert for exercise of restricted stock units by Gad Soffer, EVP Chief Strategy Officer, on 8th of March 2023. This event was filed by Atara Biotherapeutics Inc with SEC on 2017-08-17. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

A Deeper Perspective

This firm reported the previous year's revenue of 20.34 M. Net Loss for the year was (340.14 M) with loss before overhead, payroll, taxes, and interest of (229.6 M).
 2010 2022 2023 (projected)
Revenues USD20.34 M18.31 M18.2 M
Revenues20.34 M18.31 M18.2 M

Deferred Revenue Breakdown

Atara Biotherapeutics Deferred Revenue is increasing over the years with slightly volatile fluctuation. Deferred Revenue is expected to dwindle to about 104 M. Deferred Revenue usually refers to a component of Total Liabilities representing the carrying amount of consideration received or receivable on potential earnings that were not recognized as revenue; including sales; license fees; and royalties; but excluding interest income. Atara Biotherapeutics Deferred Revenue is projected to increase significantly based on the last few years of reporting. The past year's Deferred Revenue was at 110.94 Million
201061.25 Million
202196.47 Million
2022110.94 Million
2023104.04 Million

Our perspective of the current Atara Biotherapeutics rise

Current Risk Adjusted Performance is up to 0.09. Price may slip again. Atara Biotherapeutics is displaying above-average volatility over the selected time horizon. Investors should scrutinize Atara Biotherapeutics independently to ensure intended market timing strategies are aligned with expectations about Atara Biotherapeutics volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Atara Biotherapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Atara Biotherapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Conclusion on Atara Biotherapeutics

Whereas other companies under the biotechnology industry are still a bit expensive, Atara Biotherapeutics may offer a potential longer-term growth to investors. To sum up, as of the 28th of January 2023, our analysis shows that Atara Biotherapeutics hyperactively responds to market trends. The company is undervalued and projects below average probability of distress for the next 2 years. Our overall 90 days 'Buy-vs-Sell' recommendation on the company is Hold.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Atara Biotherapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com